UK-based digital health company Cumulus Neuroscience announced on Tuesday that it has entered the Japanese market via a new customer relationship with Shionogi & Co Ltd, a research-driven pharmaceutical company based in Japan.

Shionogi will leverage the Cumulus NeuLogiq Platform to generate objective neurophysiological data for S-898270, a novel therapeutic agent that selectively inhibits phosphodiesterase-4D (PDE4D) to enhance the early and late stages of memory formation. NeuLogiq is an AI-based, multi-domain digital biomarker platform that provides biopharma partners and collaborators with a suite of state-of-the-art tools to help advance the discovery and development of new therapies for neuropsychiatric and neurodegenerative conditions.

The study will be conducted in Japan, representing Cumulus' expansion into the Asian biopharma market. To support this and future studies, the NeuLogiq Platform has been translated into Japanese and Cumulus has expanded its team to support local clinical trial operations in Japan.

"We have been working with the team at Shionogi since late 2024 and are impressed by their thoughtful approach to integrating NeuLogiq digital endpoints into the S-898270 Phase 1 study protocol," said Brian Murphy, PhD, founder and chief scientific officer of Cumulus. "In July, our team presented data from CNS-101, our real-world observational study, at the Alzheimer's Association International Conference 2025 confirming that repeated home-based digital cognitive endpoints are more sensitive to disease progression than the ADAS-Cog 13 composite benchmark, the primary cognitive scale used in Alzheimer's clinical trials today to determine drug efficacy. We are confident that NeuLogiq endpoints will add discriminative power to the S-898270 study and are excited to enter the Japanese market in collaboration with the talented team at Shionogi."